by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the July 17th, 2015 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »July 17th, 2015: “EURETINA-Brief”© Issue No. 113
Inherited retinal disorders (IRDs) are estimated to affect millions of individuals on a global scale, in many instances leading to significantly reduced vision or blindness.… Read More »Converting rods into cones in a model of retinitis pigmentosa (RP) rescues retinal degeneration.
Bayer HealthCare (Bayer AG, Xetra: BAYN, Leverkusen, Germany) and the Johns Hopkins University in Baltimore, Maryland, USA, have announced the establishment of a formal collaborative… Read More »Bayer HealthCare and Johns Hopkins University sign five (5)-year collaboration agreement to develop retinal disease treatments
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of marketing authorisation for “Raxone” (idebenone), a novel… Read More »EMA’s CHMP recommends first authorisation for Leber’s Hereditary Optic Neuropathy treatment
Research, led by scientists at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, have uncovered a novel angiogenic protein involved in the… Read More »Researchers uncover potent angiogenic compound contributing to proliferative diabetic retinopathy
Inherited retinal disorders (IRDs) are estimated to affect millions of individuals on a global scale, in many instances leading to significantly reduced vision or blindness.… Read More »Converting rods into cones in a model of retinitis pigmentosa (RP) rescues retinal degeneration.
Spark Therapeutics, Inc. (NASDAQ: ONCE) and Clearside Biomedical, Inc. (Alpharetta, Georgia, USA) have announced the execution of an option agreement to facilitate a potential acquisition… Read More »Spark Therapeutics (NYSE: ONCE) executes option deal with Clearside Biomedical for ocular micro-injector technology.
A Phase II a human study led by retinal clinicians at the Retinal Consultants of Arizona in Phoenix, and sponsored by Acucela Inc., based in… Read More »Phase II clinical study of emixustat hydrochloride for treatment of geographic atrophy shows dose-dependent effect
Research, led by scientists at the University of Tokyo, has demonstrated the development of a photo-activatable Cas9 nuclease, capable of regulating CRISPR gene-editing activity through… Read More »Optogenetic CRISPR gene-editing demonstrates potential for controlling genome modifications in medical therapeutics
Inherited retinal disorders (IRDs) are estimated to affect millions of individuals on a global scale, in many instances leading to significantly reduced vision or blindness.… Read More »Converting rods into cones in a model of retinitis pigmentosa (RP) rescues retinal degeneration.